@misc{oai:repo.qst.go.jp:00072967,
 author = {Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Koizumi, Mitsuru and Kurosawa, Gene and Kurosawa, Yoshikazu and Saga, Tsuneo and Higashi, Tatsuya and 須藤 仁美 and 辻 厚至 and 須尭 綾 and 小泉 満 and 佐賀 恒夫 and 東 達也},
 month = {Sep},
 note = {CD73 plays a crucial role in adenosine-mediated immune tolerance in cancer, therefore, anti-CD73 therapy is expected to be a next-generation immune checkpoint therapy. CD73 expresses in cancer and stromal cells but not in all patients, and the expression levels are variable in patients and lesions. Monitoring CD73 status in patients is important for optimizing regimens, and noninvasive imaging with radiolabeled anti-CD73 antibody can provide helpful information. We recently developed a new fully human anti-CD73 antibody with high affinity. In this study, the utility of the antibody with a gamma-emitting radionuclide In-111 was evaluated as a molecular imaging probe in nude mice bearing tumors, MIAPaCa-2 (CD73 high) and A431 (CD73 low). The biodistribution study showed significantly higher uptake of 111In-anti-CD73 antibody in MIAPaCa-2 tumors than in A431 tumors. The SPECT/CT imaging visualized the difference of CD73 expression between MIAPaCa-2 and A431 tumors. Our data suggest that the radiolabeled anti-CD73 antibody could be a promising molecular imaging probe to select patients appropriate for CD73-targeted therapy., 第77回日本癌学会学術総会},
 title = {Development of a noninvasive imaging technique to detect the expression of CD73 mediating immunosuppression in cancer},
 year = {2018}
}